I'm wondering if the painfully slow progress teaming up with BP could in part be due to the multiple potential uses for ABL. While this is obviously a good thing, it might make the negotiations more complex. Presumably a potential partner will need to get input from many of its sections - CVD, genetics, renal, diabetes, neurology, infectious diseases, etc before coming to a valuation. Just a thought.